MUC1 Assay Portfolio Service

Organized by a staff of excellent scientists with extensive expertise in the field of immuno-oncology, Creative Biolabs is devoted to offering a full range of MUC1 assay portfolio services to support a variety of tumor-related studies.

Introduction of Tumor Target MUC1

Mucin 1 (MUC1, also known as EMA, MCA, episialin) is a type I transmembrane glycoprotein, consisting of a transmembrane, a hyperglycosylated N-terminal extracellular domain (ECD), and a C-terminal cytoplasmic tail. Normally, Mucin 1 is mainly expressed on the apical surface of most glandular epithelial cells, including the mammary gland, stomach, lung, esophagus, duodenum, pancreas and kidney, which acts as a cell surface receptor through intracellular tyrosine sites phosphorylation and interacts with various protein kinases to participate in signal transduction pathways, mediating many important cellular activities.

Fig.1 Schematic representation of normal (A) and aberrant (B) MUC1 structure. (Gao, 2020)

Aberrantly expressed glycosylated MUC1 is considered to be a tumor-specific antigen on epithelial cell tumors, which has many features, such as an increase in the expression level, loss of polarity distribution, incomplete glycosylation of the carbohydrate side chain. These characteristics confer a variety of unique roles of MUC1 in cancer progression, including its regulation of the tumor cell proliferative, invasion and metastatic potential.

MUC1 Targeted Therapeutics

To date, the development of therapeutic strategies for the overexpression and aberrant glycosylation of MUC1 in various tumors and effective approaches to MUC1-based immunotherapies are under investigation, such as MUC1-based vaccines (viral vectored vaccine, dendritic cell vaccine, glycopeptide vaccine), nanoantibodies, bispecific antibodies (anti-CD16-MUC1 bsAbs, anti-CD3-MUC1 bsAbs, anti-CD28-MUC1 bsAbs), CAR-T therapies (MUC28z CAR T, CAR-MUC1-IL22). Several clinical trials based on MUCI have observed many effective clinical responses.

Fig.2 MUC1-based clinical trials. (Creative Biolabs)

Services at Creative Biolabs

Creative Biolabs is a world-leading services provider in the field of tumor marker assay development. We are dedicated to supporting MUC1 targeted assays by designing and developing in vitro and in vivo platforms. Experienced in the immuno-oncology study, our in-home scientists are able to custom different types of MUC1 assay services to meet different purposes of projects, greatly accelerating the project research process. If you are interested in our services, please contact us to discuss your project.

Reference

1. Gao, T.; et al. A review on development of MUC1-based cancer vaccine. Biomedicine & Pharmacotherapy. 2020, 132: 110888.

For Research Use Only | Not For Clinical Use

Resources

Download our brochure